# colorectal cancer - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 3704
- Completion tokens: 20699
- Reasoning tokens: 
- Total tokens: 24403
- API requests reported: 
- Elapsed seconds: 219.67
- Final benchmark system: raw; file rank 3/5; original repeat 3; model vendor: DeepSeek

---
# 1. Overall biological interpretation

The input is a Cox proportional-hazards survival analysis of bulk colorectal tumor transcriptomes, with OS as the endpoint. Higher expression of HR > 1 genes is associated with increased mortality risk; higher expression of HR < 1 genes is associated with better survival. I interpret genes with FDR < 0.05 as the primary statistical support; genes with FDR between 0.05 and 0.08 are treated as supportive or exploratory.

The overall pattern points to two broad biological axes.

First, a poor-prognosis axis is enriched in genes that support epithelial–mesenchymal transition (EMT), TGFβ/activin signaling, cytoskeletal/motility programs, and some stromal/immune-suppressive markers. These include `INHBB`, `ZEB1-AS1`, `TPM4`, `DCBLD2`, `ABL2`, `MAP1B`, `NIN`, `ITGBL1`, `NT5E`, and `MSLN`. This is consistent with the well-established relationship between EMT, desmoplastic/stromal microenvironment, and aggressive colorectal cancer.

Second, a favorable-prognosis axis is enriched in intestinal lineage/differentiation markers and mitochondrial oxidative metabolism genes. These include `CDX2`, `CDX1`, `LGALS4`, `PRR15L`, and, separately, `NDUFA9`, `ATP5B`, `ATP5G1`, `CS`, `OGDHL`, `COA3`, `TIMM13`, and `ATP23`. This suggests that tumors retaining intestinal epithelial identity and a more oxidative, differentiated metabolic state are less aggressive.

A smaller protective theme involves antigen-processing and apoptosis-related genes such as `TAPBPL`, `LGALS9`, `CASP6`, and `BCL2L14`, suggesting that immune recognition and intact apoptotic capacity may contribute to better outcome.

The results should not be read as proof of causal gene activity. They are association-level, bulk-tissue signals that require validation and should be interpreted with attention to tumor purity and stromal/immune composition.

---

# 2. Core biological programs

## Program 1: EMT / TGFβ / invasive cytoskeletal remodeling

- **Direction**: Risk-associated; higher expression predicts worse OS.
- **Supporting genes**: `INHBB`, `ZEB1-AS1`, `TPM4`, `DCBLD2`, `ABL2`, `MAP1B`, `NIN`, `ITGBL1`, `NT5E`, `MSLN`
- **Representative pathway**: Hallmark “Epithelial Mesenchymal Transition”; Reactome “Signaling by TGF-beta family members”
- **Explanation**: `ZEB1-AS1` is an antisense lncRNA that can upregulate ZEB1, a master EMT transcription factor. `INHBB` encodes an activin/inhibin subunit that signals through TGFβ-family receptors and can promote EMT-related programs. `TPM4`, `ABL2`, `MAP1B`, and `NIN` are cytoskeletal regulators involved in actin and microtubule dynamics, migration, and invasion. `ITGBL1` is a secreted integrin-related protein associated with TGFβ signaling and stromal/CAF biology. `NT5E`/CD73 and `MSLN` are additional poor-prognosis surface/secreted proteins linked to invasion and immune evasion.
- **Evidence strength**: Moderate to strong. Multiple independent genes converge on a coherent EMT/invasion program.
- **Major limitations**: Many of these genes are also expressed by stromal or immune cells. The signal may partly reflect the amount of tumor stroma rather than purely cancer-cell-intrinsic EMT.

---

## Program 2: Oncogenic signaling and glycolytic metabolic stress

- **Direction**: Risk-associated.
- **Supporting genes**: `FGF19`, `AKT3`, `SLC2A3`, `GADD45B`, `CYP1B1`, `MIR31HG`
- **Representative pathway**: KEGG “PI3K-Akt signaling pathway”; Hallmark “Glycolysis”
- **Explanation**: `FGF19` is a growth factor ligand that can activate FGFR signaling and downstream PI3K/AKT pathways. `AKT3` is an AKT isoform directly involved in survival, proliferation, and metabolic reprogramming. `SLC2A3`/GLUT3 is a high-affinity glucose transporter supporting glycolytic metabolism. `GADD45B` can act as a stress-response survival gene. `CYP1B1` is a xenobiotic/estrogen-metabolizing cytochrome P450 enzyme associated with oxidative stress and tumor progression. `MIR31HG` is a CRC-relevant lncRNA that has been linked to poor prognosis.
- **Evidence strength**: Moderate, but less cohesive than the EMT program. These genes are linked by broad cancer progression biology rather than a single tight pathway.
- **Major limitations**: This is a heterogeneous group. `GADD45B`, `CYP1B1`, and `FGF19` have context-dependent effects and may be associated with treatment resistance or tissue composition rather than a common oncogenic mechanism.

---

## Program 3: Mitochondrial oxidative metabolism

- **Direction**: Protective; higher expression predicts better OS.
- **Supporting genes**: `NDUFA9`, `ATP5B`, `ATP5G1`, `CS`, `OGDHL`, `COA3`, `TIMM13`, `ATP23`, `PRELID2`
- **Representative pathway**: Hallmark “Oxidative Phosphorylation”; KEGG “Citrate cycle (TCA cycle)”; Reactome “Respiratory electron transport”
- **Explanation**: `NDUFA9` is a Complex I subunit; `ATP5B` and `ATP5G1` are ATP synthase subunits; `COA3` and `ATP23` participate in assembly or maturation of respiratory complexes; `TIMM13` is involved in mitochondrial protein import; `CS` and `OGDHL` are TCA-cycle enzymes. The coordinated protective direction suggests that tumors with preserved mitochondrial oxidative metabolism are less aggressive, consistent with the concept that aggressive colorectal cancers shift toward glycolysis and dedifferentiation.
- **Evidence strength**: Moderate to strong, because many independent mitochondrial genes point in the same protective direction.
- **Major limitations**: This could be influenced by tumor differentiation status, stromal content, or proliferation rate. Mitochondrial genes are expressed in all cell types, so bulk-tissue composition could contribute to the signal.

---

## Program 4: Intestinal epithelial differentiation

- **Direction**: Protective.
- **Supporting genes**: `CDX2`, `CDX1`, `LGALS4`, `PRR15L`
- **Representative pathway**: GO “intestinal epithelial cell differentiation”; KEGG “Wnt signaling pathway” as upstream regulator context
- **Explanation**: `CDX2` and `CDX1` are homeobox transcription factors that are master regulators of intestinal identity. Loss of CDX2 is a recognized marker of aggressive, poorly differentiated colorectal cancer. `LGALS4`/galectin-4 is expressed in differentiated intestinal epithelium and is frequently downregulated in colorectal cancer. `PRR15L` is less well studied but is associated with intestinal epithelial differentiation. The protective direction of these genes strongly supports the idea that retained lineage differentiation is favorable.
- **Evidence strength**: Strong biological plausibility and external clinical relevance, especially for `CDX2`.
- **Major limitations**: The number of supporting genes is relatively small. Some genes such as `MYB` also appeared protective in this dataset despite having oncogenic roles in other contexts, so the differentiation program may be broader than the four core genes listed.

---

## Program 5: Apoptosis and immune recognition

- **Direction**: Protective.
- **Supporting genes**: `CASP6`, `BCL2L14`, `TAPBPL`, `LGALS9`
- **Representative pathway**: KEGG “Apoptosis”; Reactome “Antigen processing-Cross presentation”; GO “antigen processing and presentation”
- **Explanation**: `CASP6` is an executioner caspase, and `BCL2L14` is a pro-apoptotic BCL-2 family member. `TAPBPL` is related to TAP-mediated peptide loading for MHC class I antigen presentation. `LGALS9` is a galectin involved in immune modulation, especially through TIM-3, though it has context-dependent pro- and anti-tumor effects. The combined protective direction suggests that tumors with intact apoptotic and antigen-presentation programs may be more vulnerable to immune-mediated elimination or less clinically aggressive.
- **Evidence strength**: Weak to moderate. The genes are biologically coherent but few, and `LGALS9` has conflicting literature evidence.
- **Major limitations**: `LGALS9` can promote T-cell exhaustion in some contexts, so its protective direction in this dataset may reflect a different cell compartment or a stage-specific effect.

---

# 3. Key genes and interaction modules

## 1. CDX2 / CDX1 module

- **Current direction**: `CDX2` HR 0.748, `CDX1` HR 0.781; both protective.
- **Potential role**: Maintenance of intestinal epithelial lineage identity; suppression of aggressive/dedifferentiated phenotype.
- **Gene-gene relationship**: `CDX2` and `CDX1` are paralogous homeodomain transcription factors with shared DNA-binding specificity and overlapping regulatory roles. This is best described as **regulatory / pathway co-membership**, not necessarily direct physical interaction in this dataset.

## 2. Mitochondrial OXPHOS module

- **Current direction**: `NDUFA9`, `ATP5B`, `ATP5G1`, `CS`, `OGDHL`, `COA3`, `TIMM13`, `ATP23`, `PRELID2` all protective.
- **Potential role**: Preserved mitochondrial respiration and TCA-cycle activity; favorable metabolic phenotype.
- **Gene-gene relationship**: `NDUFA9` is part of respiratory Complex I; `ATP5B` and `ATP5G1` are parts of ATP synthase. These are **direct physical subunits** of their respective complexes, but the different complexes are related by **pathway co-membership** in oxidative phosphorylation. `CS` and `OGDHL` are TCA-cycle enzymes, not physically part of the respiratory chain.

## 3. ZEB1-AS1 / EMT regulatory module

- **Current direction**: `ZEB1-AS1` HR 1.372; `INHBB` HR 1.433; `TPM4` HR 1.364; `DCBLD2` HR 1.408; `ABL2` HR 1.301; `MAP1B` HR 1.327; `NIN` HR 1.345.
- **Potential role**: EMT, invasion, TGFβ/activin signaling, cytoskeletal and microtubule remodeling.
- **Gene-gene relationship**: `ZEB1-AS1` is an antisense lncRNA that regulates ZEB1 expression, so its relationship to EMT is **regulatory**. `TPM4`, `MAP1B`, and `NIN` are cytoskeletal components/regulators related by **pathway co-membership** in actin/microtubule dynamics. `ABL2` is a kinase that regulates actin cytoskeleton, likely through **indirect/regulatory** interactions rather than physical binding with all EMT genes. `INHBB` acts upstream through TGFβ-family signaling, making its relationship to EMT **pathway/regulatory**.

## 4. NT5E / CD73 and stromal–immune interface

- **Current direction**: `NT5E` HR 1.313; `MSLN` HR 1.313; `SCARA3` HR 1.377; `GJB6` HR 1.290; `LRRC8A` HR 1.376.
- **Potential role**: `NT5E` encodes CD73, an ecto-enzyme that produces immunosuppressive adenosine. `MSLN` is a cell-surface glycoprotein associated with aggressive tumors. `SCARA3` and `GJB6` may reflect stromal/oxidative or communication-related biology.
- **Gene-gene relationship**: These genes do not clearly form a direct physical complex. They are better described as **co-members of a broader tumor-microenvironment / immune-evasion context**. `NT5E` acts on immune cells indirectly through adenosine receptor signaling.

## 5. FGF19 / AKT3 / SLC2A3 oncogenic signaling module

- **Current direction**: `FGF19` HR 1.291; `AKT3` HR 1.318; `SLC2A3` HR 1.281; `GADD45B` HR 1.324; `CYP1B1` HR 1.285.
- **Potential role**: Growth-factor signaling, PI3K/AKT survival signaling, glucose uptake, and stress metabolism.
- **Gene-gene relationship**: `FGF19` can signal through FGFR to activate PI3K/AKT, so `FGF19` and `AKT3` are linked by **pathway/regulatory** relationship. `SLC2A3` is a metabolic downstream consequence of oncogenic signaling, likely **indirect / pathway co-membership** rather than direct physical interaction with AKT3.

## 6. Apoptosis / antigen-processing module

- **Current direction**: `CASP6` HR 0.768; `BCL2L14` HR 0.760; `TAPBPL` HR 0.711; `LGALS9` HR 0.753.
- **Potential role**: Intact apoptosis and MHC class I antigen presentation; possible immune-mediated tumor control.
- **Gene-gene relationship**: `CASP6` and `BCL2L14` participate in apoptosis pathways (**pathway co-membership**). `TAPBPL` is involved in antigen processing. `LGALS9` is an immune-modulatory ligand. These are related functionally but not via direct physical interactions among all four.

---

# 4. Validation priorities

## 1. Functional validation of the EMT / TGFβ / lncRNA module

- **Classification**: Mechanistic hypothesis.
- **Why prioritize**: The EMT/TGFβ/cytoskeletal axis is one of the strongest risk-associated signals and is biologically plausible in CRC aggressiveness.
- **Current evidence**: `ZEB1-AS1`, `INHBB`, `TPM4`, `DCBLD2`, `ABL2`, `MAP1B`, and `ITGBL1` all show HR > 1 with at least marginal statistical support.
- **External evidence**: Literature strongly supports ZEB1/EMT and TGFβ signaling in CRC progression. However, TGFβ has context-dependent tumor-suppressive roles, so the direction cannot be assumed universally.
- **Next step**: CRISPRi or antisense knockdown of `ZEB1-AS1` in CRC cell lines/organoids; assess invasion, EMT markers, and response to TGFβ/activin receptor inhibitors.
- **Conclusion status**: **Supported hypothesis**, not established causality.

---

## 2. Test whether mitochondrial oxidative metabolism is prognostically protective

- **Classification**: Mechanistic hypothesis.
- **Why prioritize**: Multiple mitochondrial genes are protective, and the pattern aligns with the classic Warburg effect: aggressive tumors often downregulate oxidative metabolism.
- **Current evidence**: `NDUFA9`, `ATP5B`, `ATP5G1`, `CS`, `OGDHL`, `COA3`, `TIMM13`, `ATP23`, and `PRELID2` are all protective.
- **External evidence**: Warburg metabolism and dedifferentiation in CRC support this direction; but mitochondrial gene expression in bulk tumor can be confounded by stromal content.
- **Next step**: Perform metabolic flux analysis in patient-derived organoids or xenografts stratified by a mitochondrial score; measure oxygen consumption rate, glycolysis, and differentiation markers.
- **Conclusion status**: **Supported hypothesis**.

---

## 3. Validate CDX2/CDX1 as a differentiation-linked prognostic biomarker

- **Classification**: Biomarker.
- **Why prioritize**: CDX2 is already a clinically meaningful intestinal lineage marker, and its loss is associated with aggressive CRC.
- **Current evidence**: `CDX2` and `CDX1` are protective in this dataset; `LGALS4` and `PRR15L` support the same differentiation theme.
- **External evidence**: Numerous CRC studies associate CDX2 loss with poor differentiation and worse survival. This supports, but does not prove, the same conclusion here.
- **Next step**: Independent cohort validation with IHC for CDX2/CDX1, adjusted for stage, MSI status, and molecular subtype; assess promoter methylation and correlation with EMT scores.
- **Conclusion status**: **Supported hypothesis**; for CDX2 specifically, the underlying clinical association is already established in the literature.

---

## 4. Evaluate NT5E / CD73 as a therapeutic and immune biomarker

- **Classification**: Therapeutic target / biomarker.
- **Why prioritize**: `NT5E` is a druggable immune checkpoint-related enzyme, and CD73 inhibitors are already in oncology development.
- **Current evidence**: `NT5E` is risk-associated in this dataset (HR 1.313).
- **External evidence**: CD73 expression can suppress antitumor immunity by generating adenosine. However, having a drug is not evidence that CD73 is an effective therapeutic target in CRC; efficacy must be tested.
- **Next step**: Measure CD73 protein and activity in CRC tissue; assess immune infiltration and adenosine pathway markers; test CD73 inhibition in preclinical CRC models with high NT5E expression.
- **Conclusion status**: **Exploratory hypothesis**.

---

## 5. Determine whether the risk signal reflects tumor stroma / tumor purity

- **Classification**: Confounding or composition check.
- **Why prioritize**: Many risk genes (`ITGBL1`, `SCARA3`, `NT5E`, `INHBB`, `MSLN`) can be expressed by stromal or immune cells, while protective genes (`CDX2`, `LGALS4`) mark tumor epithelium. The survival signal may partly reflect the fraction of stroma in the bulk sample.
- **Current evidence**: The directional pattern is consistent with a stromal/EMT-rich poor-prognosis group and an epithelial/differentiated favorable group.
- **External evidence**: CRC transcriptomic subtypes, especially CMS4, are enriched for stromal/EMT gene expression and have worse survival.
- **Next step**: Apply deconvolution or signature scores (e.g., ESTIMATE, xCell, MCPcounter), perform single-cell RNA-seq or spatial transcriptomics, and adjust survival models for tumor purity and stromal score.
- **Conclusion status**: **Exploratory hypothesis**, but an essential control.

---

# 5. Evidence grounding

The interpretation uses several evidence types, which differ in independence.

- **Direct statistical evidence from the input dataset**: HR, P value, and FDR for each gene. This is the only directly quantitative dataset used.
- **Pathway/ontology evidence**: Known annotations placing genes in EMT, OXPHOS, apoptosis, antigen processing, or intestinal differentiation. This is independent of the statistical results but depends on curated prior knowledge.
- **Protein interaction / regulatory evidence**: Known relationships such as ZEB1-AS1 regulation of ZEB1, CDX2 control of intestinal differentiation, and INHBB signaling through TGFβ-family receptors. These are literature-derived and not directly demonstrated by the current dataset.
- **Disease-association evidence**: Published CRC associations for CDX2 loss, EMT, CMS4/stromal subtype, and CD73 immunosuppression. These are often related to the same prior literature that informs pathway annotations, so they are not fully independent.
- **Expression / tissue-specific evidence**: The observation that CDX2/LGALS4 are epithelial/differentiation markers, whereas ITGBL1/NT5E/SCARA3 can be stromal/immune-related. This supports the composition-confounding concern.
- **Genetic or clinical evidence**: Existing clinical data linking CDX2 loss to poor CRC outcome. This is external support, not established by the provided table.
- **Drug or therapeutic evidence**: NT5E/CD73 inhibitors exist, but this does not prove causality or efficacy in CRC.

The strongest conclusion is that the risk and protective gene sets align with two broad, biologically meaningful programs: an aggressive EMT/stromal/glycolytic phenotype and a favorable differentiated/oxidative/immune-visible phenotype. This is supported by multiple genes converging on the same pathway, which reduces the chance that the result is caused by a single-gene artifact.

---

# 6. Limitations and alternative explanations

## 1. Bulk tissue composition / tumor purity

The dataset is derived from bulk colorectal tumor tissue. Risk-associated genes such as `ITGBL1`, `SCARA3`, `NT5E`, and `INHBB` may be expressed by cancer-associated fibroblasts, endothelial cells, or immune cells. Protective genes such as `CDX2` and `LGALS4` are largely epithelial. Therefore, the survival associations may partly reflect stromal content and tumor purity rather than cancer-cell-intrinsic biology.

This can be tested by deconvolution, microdissection, single-cell RNA-seq, spatial transcriptomics, or multivariate Cox models adjusted for stromal and immune cell scores.

## 2. Unmeasured clinical confounders

OS is influenced by age, sex, tumor stage, microsatellite stability, BRAF/KRAS mutation status, and treatment exposure. The provided table does not include adjusted models or covariate information. A gene associated with OS may be a marker of stage or treatment response rather than an independent driver of prognosis.

## 3. Statistical limitations and probe ambiguity

Several genes have HRs close to 1.2–1.4 or 0.68–0.80, with FDR values near or above 0.05. Some table entries are ambiguous, for example `PROBE_*` probes, read-through loci, and multi-gene assignments such as `MSANTD3-TMEFF1|TMEFF1` or `MIR1248|SNORA81|SNORA4|SNORD2|SNORA63|EIF4A2`. These should not be used as strong evidence without independent validation.

## 4. Broad, overlapping, or context-dependent pathways

EMT, TGFβ signaling, and oxidative metabolism are broad programs with context-dependent roles. For example, TGFβ signaling is tumor-suppressive in normal and early-stage intestinal epithelium but can promote invasion and stromal remodeling in advanced CRC. Similarly, `LGALS9` can be immunosuppressive in some settings yet is protective here. `PTPN14` and `MYB` have well-known cancer-associated functions that do not obviously align with their directions in this dataset, so their roles should be treated cautiously.

## 5. Association versus causation

The survival associations are correlative. High or low expression of a gene does not prove that it drives tumor progression or protection. Reverse causation is possible: aggressive tumors may downregulate differentiation genes and mitochondrial metabolism as a consequence of oncogenic mutations, rather than these changes being the primary cause of poor outcome.

---

# Final note

The most defensible conclusion is that the transcriptomic survival signal reflects two broad CRC-relevant biological states: an aggressive, EMT/stroma-enriched and metabolically reprogrammed tumor phenotype, and a favorable, differentiated, oxidative, and immune-visible tumor phenotype. These findings are biologically plausible, supported by multiple genes, and consistent with existing CRC literature, but they remain association-level and must be validated in independent cohorts and experimental systems.
